Table 2.
Outcome | Anticipated absolute effects* (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Information statements |
---|---|---|---|---|
Pain |
SMD 1.56 SD lower (2.27 lower to 0.85 lower) |
496 (8 RCTs) |
⨁◯◯◯ a,b,c Very low |
RE may decrease pain symptoms in adults with FM |
Depression |
SMD 1.2 SD lower (2.8 lower to 0.41 higher) |
210 (3 RCTs) |
⨁◯◯◯ a,b,c,d Very low |
RE may decrease depression symptoms in adults with FM |
FIQ |
SMD 1.48 SD lower (2.24 lower to 0.73 lower) |
271 (5 RCTs) |
⨁◯◯◯ a,b,c,d,e Very low |
RE may decrease the impact of the FM on quality of life |
Mental component HRQOL |
SMD 0.3 SD higher (0.01 higher to 0.58 higher) |
211 (3 RCTs) |
⨁◯◯◯ a,c,d Very low |
RE increase Mental Component HRQOL symptoms in adults with FM |
Physical component HRQOL |
SMD 1.05 SD higher (0.66 higher to 1.43 higher) |
211 (3RCTs) |
⨁◯◯◯ a,b,c,d Very low |
RE increase Physical Component HRQOL symptoms in adults with FM |
Significant values are in bold.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% interval confidence).
aLarge number of studies with high risk of bias.
bHeterogeneity present and significant.
cDifferences in interventions and outcomes measures.
dN is under 300.
eAsymmetry in the pattern of results.